A Phase 4 interventional study of Esomeprazole and Rabeprazole in Gastro-oesophageal Reflux, sponsored by Janssen-Cilag Pty Ltd. Completed at 25 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-04-21.
Sponsored by Janssen-Cilag Pty Ltd (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies testing esomeprazole in Gastroesophageal Reflux — 1 open to participants now, 1 under way, none of them phase 3. Esomeprazole · Gastroesophageal Reflux.
Among the 67 studies testing esomeprazole in Gastroesophageal Reflux, this one is the 4th largest by enrollment of the 66 interventional ones that give a count, is one of 13 that started in 2006, is one of 28 in phase 4, and was the 29th registered.
1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.
Browse Gastroesophageal Reflux studies →1 of the 67 studies testing esomeprazole in Gastroesophageal Reflux is open now, in 1 country. Recruiting first, the newest first:
Asian Institute of Gastroenterology, India · Sites in India
Ages 18–75
By country, each count listing its studies:
Esomeprazole: first FDA approval 2001 (NEXIUM), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 3 17 · Phase 4 28
First in 2001; this study’s year is marked. 13 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,392 is above the median of 68 across 799 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 125 across the 66 interventional studies. Of the 58 that completed or were terminated, 13 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 67 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen-Cilag Pty Ltd, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen-Cilag Pty Ltd is the lead sponsor of 12 studies on the registry; none are open to participants now.
27 studies in Gastroesophageal Reflux by Johnson & Johnson: none open now, 1 under way, none of them phase 3. Of 26 finished, 9 (35%) have results posted.
Among the 27 studies in Gastroesophageal Reflux by Johnson & Johnson, this one has the largest enrollment of the 19 interventional ones that give a count, is the only one that started in 2006, is one of 4 in phase 4, and was the 4th registered.
Johnson & Johnson’s Gastroesophageal Reflux studies by the year they started, since 2001.
1 of the studies testing esomeprazole in Gastroesophageal Reflux that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06953986Asian Institute of Gastroenterology, IndiaA Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks | 2026-11-20 |
Add it to your calendar (.ics) → With an account.
Among the 67 studies testing esomeprazole in Gastroesophageal Reflux, from their registry updates:
Among Johnson & Johnson’s 27 in Gastroesophageal Reflux:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to compare, the number of patients with heartburn and regurgitation symptom resolution after treatment with either rabeprazole 20 mg, esomeprazole 20 mg or esomeprazole 40 mg.
The study is designed to be conducted in a realistic General Practice (GP) setting, enrolling typical Gastro-oesophageal Reflux Disease (GORD) patients that present for treatment, and for whom a Proton Pump Inhibitor (PPI) would normally be prescribed. The study will be conducted over a 4-week period on the basis that current GP standard practice is to treat the GORD patient for a period of 4-weeks prior to reassessment and further follow-up if required. This study is conducted in patients with GORD - associated heartburn (with or without regurgitation) at multiple GP centers, treatment is assigned based on chance (randomized), similar to the toss of a coin and neither doctor or patient knows which treatment they will receive (double-blinded). Following screening to determine eligibility, patients will be randomized to receive oral treatment with either, 20 mg rabeprazole, 20 mg esomeprazole or 40 mg esomeprazole once daily for 4 weeks. This 4-week study encompasses 2 protocol-mandated visits (baseline on day 0 and final visit on day 28). It is hypothesized that rabeprazole 20 mg will be no less effective than (non-inferior) esomeprazole 40 mg for the degree of GORD symptom resolution. Patients will take one tablet (rabeprazole 20 mg or placebo) and one capsule (esomeprazole 20 mg, esomeprazole 40 mg or placebo) each day for 28 days. The study medication will be taken once daily in the morning before breakfast, except the first dose, which will be taken during Visit 1.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Esomeprazole 40mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
Drug: Esomeprazole
Esomeprazole 20mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
Drug: Esomeprazole
Rabeprazole 20mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
Drug: Rabeprazole
20mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
20mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
40mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
The Number of Patients With Complete Resolution of Heartburn by Week 4
Complete resolution is the absence of symptoms for any 7 consecutive days within the 4 week period assessed by the PAGI-SYM scale. This likert scale describes a series of symptoms as follows: 0-None, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5 Very Severe.
Time frame: week 4 of treatment
The Number of Patients Achieving Complete Resolution of Regurgitation Symptoms at Week 4
Complete resolution is the absence of symptoms for any 7 consecutive days within the 4 week period assessed by the PAGI-SYM scale. This likert scale describes various symptoms as follows: 0-none, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5-Very Severe.
Time frame: 4 weeks
The Number of Patients Achieving Satisfactory Resolution of Heartburn by Week 4
Satisfactory resolution, which is achieved if, on any 7 consecutive days within the 4 week period, the severity of symptoms never exceeds 'mild' (symptoms must be absent, very mild, or mild) assessed by the PAGI-SYM scale. This likert scale describes various symptoms as follows: 0-none, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5-Very Severe.
Time frame: 4 weeks
The Number of Patients Achieving Satisfactory Resolution of Regurgitation Symptoms by Week 4
Satisfactory resolution, which is achieved if, on any 7 consecutive days within the 4 week period, the severity of symptoms never exceeds 'mild' (symptoms must be absent, very mild, or mild)assessed by the PAGI-SYM scale. This likert scale describes a series of symptoms as follows: 0-None, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5 Very Severe.
Time frame: 4 weeks
The Median Time to Complete Resolution of Heartburn Symptoms.
Time frame: week 4 of treatment
The Median Time to Complete Relief of Regurgitation Symptoms
Time frame: 4 weeks
The Mean Percentage of Participants With 24-hour Heartburn Symptom Free Periods
Time frame: 4 weeks
| Milestone | Rabeprazole 20 mg/Day | Esomeprazole 40 mg/Day | Esomeprazole 20 mg/Day |
|---|---|---|---|
| Started | 464 | 469 | 459 |
| Completed | 395 | 406 | 400 |
| Not completed | 69 | 63 | 59 |
| Withdrew: Adverse event | 22 | 27 | 16 |
| Withdrew: Lost to follow-up | 29 | 19 | 20 |
| Withdrew: Patient discontinued and other reasons | 17 | 17 | 23 |
| Withdrew: Physician decision | 1 | 0 | 0 |
Complete resolution is the absence of symptoms for any 7 consecutive days within the 4 week period assessed by the PAGI-SYM scale. This likert scale describes a series of symptoms as follows: 0-None, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5 Very Severe.
| participants | Rabeprazole 20 mg/Day | Esomeprazole 40 mg/Day | Esomeprazole 20 mg/Day |
|---|---|---|---|
| The Number of Patients With Complete Resolution of Heartburn by Week 4 | 272 | 302 | 278 |
| days | Rabeprazole 20 mg/Day | Esomeprazole 40 mg/Day | Esomeprazole 20 mg/Day |
|---|---|---|---|
| The Median Time to Complete Resolution of Heartburn Symptoms. | 11 (9 to 15) | 9 (7 to 10) | 12 (10 to 15) |
| days | Rabeprazole 20 mg/Day | Esomeprazole 40 mg/Day | Esomeprazole 20 mg/Day |
|---|---|---|---|
| The Median Time to Complete Relief of Regurgitation Symptoms | 9 (7 to 12) | 11 (8 to 14) | 13 (10 to 15) |
Complete resolution is the absence of symptoms for any 7 consecutive days within the 4 week period assessed by the PAGI-SYM scale. This likert scale describes various symptoms as follows: 0-none, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5-Very Severe.
| participants | Rabeprazole 20 mg/Day | Esomeprazole 40 mg/Day | Esomeprazole 20 mg/Day |
|---|---|---|---|
| The Number of Patients Achieving Complete Resolution of Regurgitation Symptoms at Week 4 | 281 | 283 | 276 |
Satisfactory resolution, which is achieved if, on any 7 consecutive days within the 4 week period, the severity of symptoms never exceeds 'mild' (symptoms must be absent, very mild, or mild) assessed by the PAGI-SYM scale. This likert scale describes various symptoms as follows: 0-none, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5-Very Severe.
| participants | Rabeprazole 20 mg/Day | Esomeprazole 40 mg/Day | Esomeprazole 20 mg/Day |
|---|---|---|---|
| The Number of Patients Achieving Satisfactory Resolution of Heartburn by Week 4 | 405 | 418 | 414 |
Satisfactory resolution, which is achieved if, on any 7 consecutive days within the 4 week period, the severity of symptoms never exceeds 'mild' (symptoms must be absent, very mild, or mild)assessed by the PAGI-SYM scale. This likert scale describes a series of symptoms as follows: 0-None, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5 Very Severe.
| participants | Rabeprazole 20 mg/Day | Esomeprazole 40 mg/Day | Esomeprazole 20 mg/Day |
|---|---|---|---|
| The Number of Patients Achieving Satisfactory Resolution of Regurgitation Symptoms by Week 4 | 397 | 413 | 402 |
| percent of participants | Rabeprazole 20 mg/Day | Esomeprazole 40 mg/Day | Esomeprazole 20 mg/Day |
|---|---|---|---|
| The Mean Percentage of Participants With 24-hour Heartburn Symptom Free Periods | 56.3 (53.1 to 59.5) | 63.4 (60.2 to 66.6) | 56.1 (52.9 to 59.3) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rabeprazole 20 mg/Day | — | 5/464 (1.1%) | 151/464 (32.5%) |
| Esomeprazole 40 mg/Day | — | 1/469 (0.2%) | 155/469 (33%) |
| Esomeprazole 20 mg/Day | — | 9/459 (2%) | 158/459 (34.4%) |
| Event | Rabeprazole 20 mg/Day | Esomeprazole 40 mg/Day | Esomeprazole 20 mg/Day |
|---|---|---|---|
| lower respiratory tract infectionInfections and infestations | 0/464 | 0/469 | 1/459 |
| alleged assaultSocial circumstances | 0/464 | 0/469 | 1/459 |
| chest painGeneral disorders | 0/464 | 0/469 | 1/459 |
| feverGeneral disorders | 0/464 | 0/469 | 1/459 |
| perianal abscess drainageSurgical and medical procedures | 0/464 | 0/469 | 1/459 |
| urinary retentionRenal and urinary disorders | 0/464 | 0/469 | 1/459 |
| depressionPsychiatric disorders | 0/464 | 0/469 | 1/459 |
| vomitingGastrointestinal disorders | 0/464 | 0/469 | 1/459 |
| hypotensionVascular disorders | 0/464 | 0/469 | 1/459 |
| meniscal tear of right kneeInjury, poisoning and procedural complications | 1/464 | 0/469 | 0/459 |
| Event | Rabeprazole 20 mg/Day | Esomeprazole 40 mg/Day | Esomeprazole 20 mg/Day |
|---|---|---|---|
| Gastrointestinal signs and symptomsGastrointestinal disorders | 63/464 | 67/469 | 54/459 |
| Gastrointestinal motility and defaecation condGastrointestinal disorders | 24/464 | 29/469 | 36/459 |
| HeadachesNervous system disorders | 19/464 | 24/469 | 31/459 |
| Infections - pathogen class unspecifiedInfections and infestations | 21/464 | 9/469 | 26/459 |
| Viral infectious disordersInfections and infestations | 9/464 | 6/469 | 13/459 |
| Neurological disorders NECNervous system disorders | 9/464 | 9/469 | 11/459 |
| Salivary gland conditionsGastrointestinal disorders | 2/464 | 8/469 | 4/459 |
| Joint disordersMusculoskeletal and connective tissue disorders | 2/464 | 8/469 | 3/459 |
| Musculoskeletal and connective tissue disorders NECMusculoskeletal and connective tissue disorders | 7/464 | 8/469 | 6/459 |
| Muscle disordersMusculoskeletal and connective tissue disorders | 4/464 | 2/469 | 4/459 |
| Age, Continuous(years) | Rabeprazole 20 mg/Day | Esomeprazole 40 mg/Day | Esomeprazole 20 mg/Day | Total |
|---|---|---|---|---|
| Mean | 45.8 ± 14.8 | 48 ± 14.7 | 46.2 ± 14.8 | 46.7 ± 14.8 |
| Sex: Female, Male(Participants) | Rabeprazole 20 mg/Day | Esomeprazole 40 mg/Day | Esomeprazole 20 mg/Day | Total |
|---|---|---|---|---|
| Female | 204 | 208 | 208 | 620 |
| Male | 260 | 261 | 251 | 772 |
| Region of Enrollment(participants) | Rabeprazole 20 mg/Day | Esomeprazole 40 mg/Day | Esomeprazole 20 mg/Day | Total |
|---|---|---|---|---|
| Australia | 464 | 469 | 459 | 1392 |
The record gives a start of Nov 2006, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2010, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Esomeprazole · Rabeprazole